Note 1: Segment Information continued The table reconciles statutory results for key line items to the segment report. Statutory results Impairment and amortisation of acquired IP Unwind of CSL Vifor inventory fair value uplift CSL Vifor acquisition and integration costs Tax impacts of the adjustments Segment results Year ended 30 June (US$m) 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Gross profit 7,671 6,825 301 235 30 169 4 2 — — 8,006 7,231 Selling and marketing expenses (1,573) (1,481) — — — — 17 — — — (1,556) (1,481) Research and development expenses (1,430) (1,269) — — — — 2 3 — — (1,428) (1,266) General and administrative expenses (856) (1,006) — — — — 31 179 — — (825) (827) EBIT/Underlying EBIT 3,812 3,069 301 235 30 169 54 184 — — 4,197 3,657 Profit before tax 3,375 2,663 301 235 30 169 54 184 — — 3,760 3,251 NPAT/NPATA 2,714 2,244 301 235 30 169 54 184 (61) (85) 3,038 2,747 – NPAT/NPATA attributable to CSL shareholders 2,642 2,194 241 181 20 122 54 184 (50) (71) 2,907 2,610 – NPAT/NPATA attributable to noncontrolling interests 72 50 60 54 10 47 — — (11) (14) 131 137 Basic earnings per share/NPATA per share (US$) 5.47 4.55 0.50 0.38 0.04 0.25 0.11 0.38 (0.10) (0.15) 6.02 5.41 Certain comparative amounts have been reclassified in order to be consistent with the current year's presentation. The overall impact of such reclassifications had no impact on net profit. Segment assets and liabilities CSL Behring CSL Seqirus CSL Vifor Consolidated Entity US$m US$m US$m US$m 2024 2023 2024 2023 2024 2023 2024 2023 Segment assets 23,635 22,026 4,403 3,980 9,984 10,228 38,022 36,234 Segment liabilities 15,373 14,903 1,415 1,384 1,833 2,121 18,621 18,408 Segment assets and liabilities disclosed above exclude intercompany receivables, payables and investments in subsidiaries which have been eliminated. Other segment information Cash payments for property, plant and equipment (PPE) 615 869 212 326 22 33 849 1,228 Cash payments for intangibles 165 83 156 292 88 89 409 464 Cash payments for PPE during the year ended 30 June 2024 includes investment made into the new cell-based influenza vaccine manufacturing facility in Tullamarine, Australia and continued investment in the Group's R&D facilities including in Marburg, Germany and Waltham, United States. Further, cash payments for intangibles during the year ended 30 June 2024 includes development milestones paid in connection with the Group's licensing arrangements including with Arcturus Therapeutics Holdings Inc and uniQure. 114 Notes to the Financial Statements Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3